NL-OMON23733尚未招募不适用
A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 36
研究概览
简要总结
n/a
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age ≥18 and ≤75 years
- •-Diagnosis of type 2 diabetes mellitus
- •-HbA1c ≥ 6.6% and <11.0%
- •-Urinary albumin excretion > 100 mg/g
- •-On a stable dose of an ACEi or ARB for at least 4 weeks prior to randomization
- •-On a stable dose of blood glucose lowering medication for at least 4 weeks prior to randomization
- •-eGFR ≥ 45 mL/min/1.73m2
- •-Willing to sign informed consent
排除标准
- •Type 1 diabetes
- •Urinary albumin excretion > 3500 mg/day
- •Active malignancy
- •Pregnancy or breast feeding
研究者
相似试验
进行中（未招募）
不适用
A study to examine whether the glucose lowering medicine dapagliflozin decreases urinary protein excretion and to determine the variation in response to dapagliflozin in plasma glucose / urinary protein excretion / blood pressure between and within patients.Patients with type 2 diabetes and albuminuria between 100 and 3500 mg/g.EUCTR2014-000157-37-NLniversity Medical Center Groningen
已完成
4 期
A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetesAlbuminuria in patients with type 2 diabetes1001265310029149NL-OMON40930niversitair Medisch Centrum Groningen36
尚未招募
4 期
Comparing Medications for Reducing Kidney Damage in Diabetes: A Study on Dapagliflozin Alone and with EplerenoneCTRI/2024/01/061952Dr Nikhil Kumar
招募中
2 期
The effect of albumin administration on mortality rate, lung involvement rate and blood oxygen in patients with covid-19 hospitalized in the intensive care unitIRCT20221011056144N1Karaj University of Medical Sciences52
已完成
4 期
Efficacy of Albumin for Acute Encephalopathy in Patients With CirrhosisHepatic EncephalopathyNCT00886925Hospital Universitari Vall d'Hebron Research Institute56